Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening
- 8 January 2010
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 30 (3) , 229-234
Abstract
Objective: To investigate whether a significantly aberrant expression of circulating placental mRNA genes related with cardiogenesis can be detected at the second trimester of pregnancy.Methods: The study was performed in two stages. First stage (development model group): match of 14 placental tissues at delivery of fetuses with congenital heart disease versus 20 controls. Second stage (validation model group): mRNA amplification of abnormal expressed genes in maternal blood samples from 26 women bearing a fetus with a congenital heart disease matched with 28 controls.Results: We identified four functional categories of genes possibly involved in abnormal heart development: cardiac morphogenesis: tenascin, thioredoxin, salvador homolog 1 protein; extracellular matrix (ECM) and valvular tissue biosynthesis; placental‐associated plasma protein, collagen, type I, alpha 2, fibulin‐1, heparanase, procollagen‐proline, 2‐oxoglutarate 4‐dioxygenase, alpha polypeptide II, Jumonji, AT rich interactive domain 1B RBP2‐like; normal contractile activity: actinin, alpha 4, fascin homolog 1, actin‐bundling protein; and congestive heart failure.Conclusion: Altered placental genetic expression was found at term delivery in affected fetuses. The aberration was also confirmed in maternal blood at the second trimester of women bearing a fetus with congenital heart disease. Sensitivity for the most aberrant genes ranged between 42% and 95% at a false positive rate (FPR) of 10%. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 32 references indexed in Scilit:
- Hearts and bones: Shared regulatory mechanisms in heart valve, cartilage, tendon, and bone developmentDevelopmental Biology, 2006
- Is measurement of nuchal translucency thickness a useful screening tool for heart defects? A study of 16 383 fetusesUltrasound in Obstetrics & Gynecology, 2006
- Identification of differentially expressed genes in human heart with ventricular septal defect using suppression subtractive hybridizationBiochemical and Biophysical Research Communications, 2006
- Evidence of genetic underexpression in chorionic villi samples of euploid fetuses with increased nuchal translucency at 10–11 weeks' gestationPrenatal Diagnosis, 2006
- Hot hearts in the Sonoran desert: The 11th Weinstein cardiovascular development conference in TucsonDevelopmental Dynamics, 2005
- The influence of prenatal diagnosis on postnatal outcome in patients with structural congenital heart diseasePrenatal Diagnosis, 2004
- Genetic modification of the heart: chaperones and the cytoskeletonJournal of Molecular and Cellular Cardiology, 2004
- Evaluation of the jumonji gene and risk for spina bifida and congenital heart defectsAmerican Journal of Medical Genetics Part A, 2003
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001
- Microtubule Stabilization in Pressure Overload Cardiac HypertrophyJournal of Cell Biology, 1997